Production (Stage)
MoonLake Immunotherapeutics
MLTX
$46.88
-$1.95-3.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | -12.23% | -12.32% | -0.41% | 3.59% | 767.65% |
| Total Receivables | 99.75% | 169.01% | 233.95% | 170.54% | 295.32% |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 359.31% | 1,013.99% | 382.87% | 288.99% | 63.83% |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | -8.55% | -7.76% | 2.46% | 6.03% | 732.41% |
|
|
|||||
| Total Current Assets | -8.55% | -7.76% | 2.46% | 6.03% | 732.41% |
| Net Property, Plant & Equipment | -21.58% | -7.72% | 1,734.66% | 1,422.32% | 1,339.23% |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -73.13% | -- | -- | -- | -- |
| Total Assets | -9.37% | -9.23% | 3.60% | 7.55% | 744.53% |
|
|
|||||
| Total Accounts Payable | -93.14% | -31.99% | -29.09% | -21.95% | 216.28% |
| Total Accrued Expenses | 219.39% | 150.53% | 150.38% | 48.58% | -6.52% |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 9.78% | 14.53% | 824.44% | 735.46% | 740.46% |
| Total Finance Division Other Current Liabilities | 113.57% | 74.48% | -82.44% | 1,541.98% | 302.27% |
| Total Other Current Liabilities | 113.57% | 74.48% | -82.44% | 1,541.98% | 302.27% |
| Total Current Liabilities | 169.13% | 125.41% | 94.81% | 72.15% | 22.41% |
|
|
|||||
| Total Current Liabilities | 169.13% | 125.41% | 94.81% | 72.15% | 22.41% |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -51.56% | -41.70% | 14,676.34% | 3,715.66% | 2,487.82% |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 15.84% | 6.39% | 172.12% | 67.46% | 47.26% |
| Total Liabilities | 741.21% | 88.08% | 114.74% | 97.65% | 52.65% |
|
|
|||||
| Common Stock & APIC | 1.56% | 11.06% | 27.12% | 13.98% | 410.37% |
| Retained Earnings | -111.41% | -101.95% | -73.95% | -54.92% | -45.37% |
| Treasury Stock & Other | -11.37% | 111.94% | -1.43% | 9,178.92% | 691.86% |
| Total Common Equity | -24.89% | -9.86% | 14.89% | 6.30% | 1,191.82% |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | -24.89% | -9.86% | 14.89% | 6.30% | 1,191.82% |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -48.53% | -63.14% | -88.71% | 0.59% | -42.54% |
| Total Equity | -25.31% | -11.70% | 1.20% | 6.20% | 834.47% |
|
|
|||||